ArticleMolecular oncology2026
CEACAM1 participation in breast cancer progression.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is widely expressed in human cells and undergoes marked alterations during tumorigenesis. However, its functional significance in invasive breast cancer (BC) remains insufficiently understood. In this study, CEACAM1 expression patterns in invasive BC tissues were analyzed and correlated with the proliferative index (PI) of the tumor cells. To assess isoform-specific functional effects and identify CEACAM1-responsive genes involved in key proliferation-associated pathways, MCF-7 cells were transfected with either CEACAM1 short cytoplasmic domain isoform (CEACAM1-4S) or CEACAM1 long cytoplasmic domain isoform (CEACAM1-4L). BC tissues exhibited substantial heterogeneity in CEACAM1 expression, which correlated with the PI of the tumor cells. Functional in vitro studies demonstrated that the CEACAM1-4L isoform exclusively suppresses cell proliferation. Transcriptome and protein-level analyses revealed that CEACAM1-4L regulates the expression of key mediators involved in cell cycle control, apoptosis, extracellular matrix organization, and growth factor-dependent signaling pathways. These findings highlight the biological significance of CEACAM1-4L isoform in BC, its potential diagnostic relevance for patient stratification, as well as its possible consideration in future therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.